Integrated serum pharmacochemistry and network pharmacological analysis used to explore possible anti-rheumatoid arthritis mechanisms of the Shentong-Zhuyu decoction

Lin Wang,Xiulan Pu,Xin Nie,Di Wang,Huajuan Jiang,Yi Chen,Lan Pang,Shengju Wang,Xiao Wang,Zhiyi Xu,Chaomei Fu,Dasheng Lin,Jinming Zhang
DOI: https://doi.org/10.1016/j.jep.2021.113988
IF: 5.195
2021-06-01
Journal of Ethnopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethnopharmacological relevance</h3><p>Shentong-Zhuyu decoction (STZYD) has been recognized by the Chinese National Administration of Traditional Chinese Medicine (TCM) as a classic TCM formula. Use of STZYD has shown a satisfactory clinical therapeutic outcome for rheumatoid arthritis (RA); despite this, its bioactive chemical composition and relevant mechanism(s) of this action have not been clearly elucidated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of the study</h3><p>To explore the bioactive chemical composition of STZYD used for RA treatment and its possible mechanism(s) of action.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>Serum pharmacochemistry mediated by the UPLC-Q-Exactive MS/MS method was employed to identify the absorbed phytochemical compounds in serum derived from STZYD, which were commonly considered as the potential bioactive compounds. And then, these components were used to construct a compound-target network for RA using a network pharmacology approach, to predict the possible biological targets of STZYD along with potential signaling pathways. Afterwards, we established a Complete Freund's adjuvant (CFA)-induced RA rat model, and observed the anti-RA effect of STZYD by a series of indexes, including foot swelling, ankle diameter, arthritis score, morphological and radiographic analysis, serum inflammatory factors, and histopathological analysis of synovial tissues. Particularly, the predicted pathway by the combination of serum pharmacochemistry and network pharmacology was further validated using RT-qPCR, Western blot, and immunohistochemical analyses in animal experiment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Totally, 38 compounds derived from STZYD have been identified by serum sample analysis. Based on it, 387 genes related to these identified compounds in STZYD and 3807 genes related to RA were collected by network pharmacology. Critically, KEGG analysis indicated that the PI3K/AKT signaling pathway was recommended as one of the main pathway related to anti-RA effect of STZYD. Experimentally, STZYD significantly alleviated CFA-induced arthritis without any visible side-effects. Compared to the RA model group without any treatment, the treatment of STZYD significantly reduced the expression of both mRNA and protein targets in the PI3K/AKT signaling pathway. Furthermore, this result was also corroborated by immunohistochemistry analysis. All these studies could effectively corroborate the predicted result as above, suggested that the feasibility of this integrated strategy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>This study provided a useful strategy to identify bioactive compounds and the potential mechanisms for TCM formula by integrating serum pharmacochemistry and network pharmacology.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
What problem does this paper attempt to address?
The paper primarily explores the mechanism of action and active components of Shentong Zhuyu Decoction (STZYD) in the treatment of rheumatoid arthritis (RA). Specifically, the study aims to: 1. **Identify the effective chemical components of STZYD for treating RA**: Using serum pharmacochemistry methods combined with ultra-high-performance liquid chromatography-Orbitrap high-resolution mass spectrometry (UPLC-Q-Exactive MS/MS), researchers identified the active components in STZYD that may be involved in treating RA. 2. **Explore the potential mechanism of action of STZYD**: By employing network pharmacology methods, a compound-target network was constructed to predict the pathways through which STZYD acts on RA. The analysis revealed that the PI3K/AKT signaling pathway might be one of the key mechanisms by which STZYD treats RA. 3. **Validate the anti-RA effects and mechanisms of STZYD**: Using a rat RA model induced by complete Freund's adjuvant (CFA), the efficacy of STZYD was evaluated. The effects were observed through a series of indicators such as paw swelling, ankle diameter, arthritis score, morphological and radiological analyses. Additionally, experiments such as real-time fluorescence quantitative PCR (RT-qPCR), Western blot, and immunohistochemical analysis were conducted to verify whether the PI3K/AKT signaling pathway is involved in the anti-RA action of STZYD. In summary, this study, by combining serum pharmacochemistry and network pharmacology methods, not only identified the active components in STZYD but also preliminarily revealed its molecular mechanism in treating RA, providing new ideas and methods for the modern scientific research of traditional Chinese medicine.